Search Results
Found 1 results
510(k) Data Aggregation
(284 days)
The ACCLARENT AERATM Eustachian Tube Balloon Dilation System is intended to dilate the Eustachian tube for treatment of persistent Eustachian tube dysfunction in adults ages 22 and older.
The ACCLARENT® AERA™ Eustachian Tube Balloon Dilation System includes the Eustachian Tube Balloon Catheter (ETBC) and the Eustachian Tube Guide Catheter (ETGC). The system is provided with the following additional devices: the Acclarent SE Inflation Device (or Acclarent Balloon Inflation Device) and Relieva Extension Tubing. The Acclarent SE Inflation Device (or Acclarent Balloon Inflation Device) is used to inflate the ETBC. The Acclarent SE Inflation Device and Acclarent Balloon Inflation Device are FDA cleared devices (K150172 and K052198, respectively). The Relieva Extension Tubing may be used to connect the Balloon Catheters and the Inflation Device when additional tubing length is required. The Relieva Extension Tubing is a Class I exempt device under 21 CFR 874.4420. All devices are provided sterile for single-patient use.
The ETBC is a 6x16mm (inflated diameter x length) flexible Balloon Catheter (Figure 1) with an integrated shaft and a nylon balloon at the distal tip. The non-compliant balloon is designed to dilate the cartilaginous portion of the Eustachian tube (ET). The shaft consists of dual lumen tubing with an actuator component that is designed to assist in rotation and advancement of the ETBC. The balled catheter tip (aka, "blueberry tip") on the ETBC is designed to restrict advancement of the device into the bony portion of the ET, known as the isthmus. There is an endoscopic marker placed at the proximal taper of the balloon to aid in positioning under direct endoscopic visualization.
The ETGC (Figure 2) is designed to facilitate ETBC access to the ET. The ETGC incorporates an atraumatic distal tip and distal angled tip profile that facilitates access to the ET. The ETGC contains a lubricious inner liner to allow smooth passage for the ETBC and includes a hypotube for rigidity.
Here's an analysis of the acceptance criteria and the study proving the device meets them, based on the provided text:
ACCLARENT AERA™ EUSTACHIAN TUBE BALLOON DILATION SYSTEM
1. Table of Acceptance Criteria and Reported Device Performance
The provided text details various non-clinical/bench studies and a clinical study that demonstrate the device's performance against specific criteria.
Non-Clinical/Bench Studies Acceptance Criteria and Performance:
| Test Name | Acceptance Criteria | Reported Performance |
|---|---|---|
| Biocompatibility | ||
| Cytotoxicity | Acceptable per ISO 10993-5:2009 | Accepted |
| Sensitization | Acceptable per ISO 10993-10:2010 | Accepted |
| Irritation | Acceptable per ISO 10993-10:2010 | Accepted |
| Acute Systemic Toxicity | Acceptable per ISO 10993-11:2006 | Accepted |
| Sterilization & Shelf Life | ||
| Sterilization Validation | Sterility assurance level (SAL) of 10^-6 | Passed |
| Ethylene Oxide Residuals | Ethylene oxide (EO) redacted (b(4) CCI) | Passed |
| Tensile Strength | Force at break ≥ redacted (b(4) CCI) | Passed |
| Balloon Catheter Tip Test | Force at break ≥ redacted (b(4) CCI) | Passed |
| Insertion/Retraction Test | After 4 insertion/retractions without structural damage or balloon leakage | Passed |
| Fatigue Test | 8 cycles @ redacted (b(4) CCI) without failure | Passed |
| Label | Visual confirmation of correct label | Passed |
| Guide Catheter Performance | ||
| Dimensional | Per device design specifications | Passed |
| Fatigue | After 4 insertion/retraction cycles without failure | Passed |
| Materials | Visual confirmation that materials are clear/translucent for visibility | Passed |
| Torque | Torque ≥ redacted (b(4) CCI) | Passed |
| Tensile Strength | Force at break ≥ redacted (b(4) CCI) | Passed |
| Label | Visual confirmation of correct label | Passed |
Cadaver Study Acceptance Criteria and Performance:
| Test Name | Acceptance Criteria | Reported Performance |
|---|---|---|
| Simulated Use in Cadavers (Overall Performance) | Clinically acceptable rating of "2" or higher on a 1-4 point scale (4 = excellent, 1 = clinically unacceptable) | All ratings from each evaluator were above "2". The lowest average rating for any requirement was 3.3, and the highest was 3.7 out of 4. System performed as intended with no safety issues. |
Clinical Study Acceptance Criteria and Performance:
| Endpoint | Acceptance Criteria | Reported Performance |
|---|---|---|
| Primary Efficacy | Superiority of ET balloon dilation + medical management vs. medical management alone, demonstrated by a significantly higher proportion of subjects experiencing normalization of tympanometry at 6 weeks post-treatment. | Tympanogram normalization observed in 51.8% (73/141) of investigational subjects vs. 13.9% (10/72) controls (p |
Ask a specific question about this device
Page 1 of 1